Login / Signup

Glepaglutide, a novel glucagon-like peptide-2 agonist, has anti-inflammatory and mucosal regenerative effects in an experimental model of inflammatory bowel disease in rats.

Jolanta SkarbalieneJesper Mosolff MathiesenBjarne Due LarsenChristian ThorkildsenYvette Miata Petersen
Published in: BMC gastroenterology (2023)
Glepaglutide has anti-inflammatory and intestinotrophic effects without the need for pre-treatment in a rat model of small intestinal inflammation. Thus, glepaglutide is of potential clinical interest for patients with IBD.
Keyphrases
  • anti inflammatory
  • stem cells
  • oxidative stress
  • ulcerative colitis
  • mesenchymal stem cells
  • cell therapy
  • risk assessment
  • climate change